Diagnostic histochemistry and clinical-pathological testings as molecular pathways to pathogenesis and treatment of the ageing neuromuscular system: A personal view

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 4, 2015, Pages 563-584

  Engel, W King ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Ageing muscle atrophy; Amyotrophic Lateral Sclerosis; Human muscle histochemistry; IVIG treatment; Multicramps; Treatable diabetic neuropathy

Indexed keywords

ACETAZOLAMIDE; ACID PHOSPHATASE; ALPHA2A INTERFERON; CALCIUM; GLUCOCORTICOID; IMMUNOGLOBULIN G; MYOSTATIN; PROTEASOME; TRANSCRIPTION FACTOR FOXO; UBIQUITIN;

AGING; AMYOTROPHIC LATERAL SCLEROSIS; ANTIGEN ANTIBODY COMPLEX; CACHEXIA; CALCIUM CELL LEVEL; CELL AGING; CELL VACUOLE; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EBOLA HEMORRHAGIC FEVER; EXTRACELLULAR CALCIUM; FAST MUSCLE FIBER; FATIGUE; HEREDITARY MOTOR SENSORY NEUROPATHY; HISTOCHEMISTRY; HUMAN; HYPOACTIVITY; LEUKOCYTE; LYSOSOMAL VACUOLAR MYOPATHY; MITOCHONDRIAL MYOPATHY; MOTONEURON; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE REINNERVATION; MYASTHENIA GRAVIS; MYOPATHY; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASE; NEUROMUSCULAR SYSTEM; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; SENSORY NERVE CELL; SLOW MUSCLE FIBER; SUBACUTE COMBINED DEGENERATION; SYSTEMIC THERAPY; WEAKNESS; WHOLE BODY RADIATION; GENETICS; METABOLISM; NEUROMUSCULAR DISEASES; PATHOLOGY;

AGING; HUMANS; NEUROMUSCULAR DISEASES;

EID: 84922331573     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.11.015     Document Type: Review

References (134)

1. Hawking S. A brief history of time 1988, Bantam Books.
2. Afshordi N. The Black Hole at the Beginning of Time, Scientific American 2014, 38-43.
3. Shakespeare W. Hamlet, Act 3, scene 1. 1603.
4. Engel W.K. The essentiality of histo- and cytochemical studies of skeletal muscle in the investigation of neuromuscular disease. Neurology 1962, 12:778-794.
5. Engel W.K., Cunningham G.G. Rapid examination of muscle tissue and improved trichrome method for fresh-frozen biopsy sections. Neurology 1963, 13:919-923.
6. Askanas V., Engel W.K., Alvarez R.B. Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology 1993, 43:1265-1267.
7. Schiaffino S., Dyar K., Ciciliot S., Blaauw B., Sandri M. Mechanisms regulating skeletal muscle growth and atrophy. FEBS J. 2013, 280:4294-4314.
8. Campa J.F., Engel W.K. Histochemical and functional correlations in anterior horn neurons of the cat spinal cord. Science 1971, 171:198-199.
9. Campa J.F., Engel W.K. Histochemistry of motor neurons and interneurons in the cat lumbar spinal cord. Neurology 1970, 20:559-568.
10. Campa J.F., Engel W.K. Histochemical classification of anterior horn neurons. Neurology 1970, 20:386.
11. Burke R.E., Levine D.N., Zajac F.E. Mammalian motor units: physiological-histochemical correlation in three types in cat gastrocnemius. Science 1971, 174:709-712.
12. Burke R.E., Tsairis P., Levine N. Direct correlation of physiological and histochemical characteristics of motor units of cat triceps surae muscle. New developments in electromyography and clinical neurophysiology 1973, 23-30. Karger, Basel. J.E. Desmedt (Ed.).
13. Warmolts J.B., Engel W.K. Correlation of motor unit behavior with histochemical and myofiber type in humans by open-biopsy electromyography. New developments in electromyography and clinical neurophysiology 1973, 35-40. Karger, Basel. J.E. Desmedt (Ed.).
14. Engel W.K., Irwin R.L. A histochemical-physiological correlation of frog skeletal muscle fibers. Am. J. Physiol. 1967, 213:511-518.
15. Warmolts J.R., Engel W.K. Open-biopsy electromyography. I. Correlation of motor unit behavior with histochemical muscle fiber type in human limb muscle. Arch. Neurol. 1972, 27:512-517.
16. Engel W.K., Askanas V. Aging of the human neuromuscular system: Pathological aspects. Muscle aging, inclusion-body myositis and myopathies 2012, 3-32. Wiley-Blackwell. V. Askanas, W.K. Engel (Eds.).
17. Engel W.K., Askanas V. Aging of the human neuromuscular system: clinical considerations. Muscle aging, inclusion-body myositis and myopathies 2012, 33-54. Wiley-Blackwell. V. Askanas, W.K. Engel (Eds.).
18. Engel W.K., Brooke M.H., Nelson P.G. Histochemical studies of denervated or tenotomized cat muscle: illustrating difficulties in relating experimental animal conditions to human neuromuscular diseases. Ann. N. Y. Acad. Sci. 1966, 138:160-185.
19. Timchenko L. Molecular mechanisms of muscle atrophy in myotonic dystrophies. Int. J. Biochem. Cell Biol. 2013, 45:2280-2287.
20. Engel W.K. Muscle fiber hypotrophy with central nuclei. Scientific approaches to clinical neurology 1977, 1572-1600. Lea Febiger, Philadelphia. E.S. Goldensohn, S.H. Appel (Eds.).
21. Lee I.-C., Su P.-H., Chen J.-Y., Hu J.-M., Lu J.-J., Ng Y.-Y. Congenital myotubular myopathy with a novel MTM1 gene mutation in a premature infant presenting with ventilator dependency and intrahepatic cholestasis. J. Child Neurol. 2012, 27:99-104.
22. Padykula H.A., Herman E. Factors affecting the activity of adenosine triphosphatase and other phosphatases as measured by histochemical techniques. J. Histochem. Cytochem. 1955, 3:161-169.
23. Drews G.A., Engel W.K. Reversal of the ATPase reaction in muscle fibres by EDTA. Nature 1966, 212:1551-1553.
24. Engel W.K. Muscle biopsy. Clin. Orthop. Relat. Res. 1965, 39:80-105.
25. Pearse A.G. Direct relationship of phosphorylase and mitochondrial alpha-glycerophosphate dehydrogenase activity in skeletal muscle. Nature 1961, 191:504.
26. Brooke M.H., Kaiser K.K. Muscle fiber types: how many and what kind?. Arch. Neurol. 1970, 23:369-379.
27. Hogenhuis L.A., Engel W.K. Histochemistry and cytochemistry of experimentally denervated guinea Pig muscle. I. Histochemistry. Acta Anat. (Basel) 1965, 60:39-65.
28. Karpati G., Engel W.K. Transformation of the histochemical profile of skeletal muscle by "foreign" innervation. Nature 1967, 215:1509-1510.
29. Karpati G., Engel W.K. Correlative histochemical study of skeletal muscle after suprasegmental denervation, peripheral nerve section, and skeletal fixation. Neurology 1968, 18:681-692.
30. Karpati G., Engel W.K. "Type grouping" in skeletal muscles after experimental reinnervation. Neurology 1968, 18:447-455.
31. Karpati G., Engel W.K. Histochemical investigation of fiber type ratios with the myofibrillar ATP-ase reaction in normal and denervated skeletal muscles of guinea pig. Am. J. Anat. 1968, 122:145-155.
32. Ringel S.P., Engel W.K., Bender A.N. Extrajunctional acetylcholine receptors on myogenously de-innervated muscle fibers. J. Histochem. Cytochem. 1976, 24:1033-1034.
33. Engel W.K., Cunningham G.G. Alkaline phosphatase-positive abnormal muscle fibers of humans. J. Histochem. Cytochem. 1970, 18:55-57.
34. Mendell J.R., Engel W.K. The fine structure of type II muscle fiber atrophy. Neurology 1971, 21:358-365.
35. Pleasure D.E., Walsh G.O., Engel W.K. Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch. Neurol. 1970, 22:118-125.
36. Engel W.K. Selective and nonselective susceptibility of muscle fiber types. A new approach to human neuromuscular diseases. Arch. Neurol. 1970, 22:97-117.
37. Mitch W.E., Goldberg A.L. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N. Engl. J. Med. 1996, 335:1897-1905.
38. Cohen S., Lee D., Zhai B., Gygi S.P., Goldberg A.L. Trim32 reduces PI3K-Akt-FoxO signaling in muscle atrophy by promoting plakoglobin-PI3K dissociation. J. Cell Biol. 2014, 204:747-758.
39. Engel W.K. Multi-microcramps syndrome:a new pathogenic concept of subtle lower motor-neuron lability causing very disturbing, continuing muscle pains, sometimes gratifying treatable-but often misdinterpreted as mysterious "fibromyalgia" or "psychgenic". Neurology 2010, 74:A465.
40. Patten B., Bilezikian J.P., Mallette L.E., et al. Neuromuscular disease in primary hyperparathyroidism. Ann. Intern. Med. 1973, 80:182-193.
41. Engel W.K. Muscle target fibres, a newly recognized sign of denervation. Nature 1961, 191:389-390.
42. Askanas V., Engel W.K., Alvarez R.B., Broccolini A. Myotonic dystrophy muscle nuclei have features of apoptosis "Apoptosis-Lente", PS-1 accumulation, and contain filamentous inclusions and ubiquitin immunoreactivity. Neurology 1999, 52:94.
43. Blaauw B., Schiaffino S., Reggiani C. Mechanisms modulating skeletal muscle phenotype. Comprehensive physiology 2011, John Wiley & Sons, Inc.
44. Sandri M., Barberi L., Bijlsma A.Y., Blaauw B., Dyar K.A., Milan G., Mammucari C., Meskers C.G.M., Pallafacchina G., Paoli A., Pion D., Roceri M., Romanello V., Serrano A.L., Toniolo L., Larsson L., Maier A.B., Muñoz-Cánoves P., Musarò A., Pende M., Reggiani C., Rizzuto R., Schiaffino S. Signalling pathways regulating muscle mass in ageing skeletal muscle. The role of the IGF1-Akt-mTOR-FoxO pathway. Biogerontology 2013, 14:303-323.
45. Sartori R., Schirwis E., Blaauw B., Bortolanza Z., Zhao J., Enzo E., Stantzou A., Mouisel E., Toniolo L., Ferry A., Stricker S., Goldberg A.L., Dupont S., Piccolo S., Amthor H., Sandri M. BMP signaling controls muscle mass. Nat Genet. 2013, 45:1309-1318.
46. Goldberg A.L. New insight into the molecular mechanism of muscle atrophy. J. Neuromuscul. Dis. 2014, 1:s34.
47. Brault J.J., Jespersen J.G., Goldberg A.L. Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J. Biol. Chem. 2010, 285:19460-19471.
48. Lee D., Goldberg A.L. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth. J Biol Chem. 2013, 288:30515-30526.
49. Schiaffino S., Reggiani C. Fiber types in mammalian skeletal muscles. Physiol. Rev. 2011, 91:1447-1531.
50. Sandri M. Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome. Int. J. Biochem. Cell Biol. 2013, 45:2121-2129.
51. Cohen S., Brault J.J., Gygi S.P., Glass D.J., Valenzuela D.M., Gartner C., Latres E., Goldberg A.L. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J. Cell Biol. 2009, 185:1083-1095.
52. Zhao J., Brault J.J., Schild A., Goldberg A.L. Coordinate activation of autophagy and the proteasome pathway by FoxO transcription factor. Autophagy 2008, 4:378-380.
53. Special issue: Molecular basis of muscle wasting. Int. J. Biochem. Cell Biol. 2013, 45.
54. Engel W.K. Dagen des oordeels. Pathokinetic mechanisms and molecular messengers (a dramatic view). Arch. Neurol. 1979, 36:329-339.
55. Askanas V., Engel W.K. Sporadic inclusion-body myositis: Conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-beta42 oligomers and phosphorylated tau. Presse Med. 2011, 40:e219-e235.
56. Nogalska A., Wojcik S., Engel W.K., McFerrin J., Askanas V. Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp. Neurol. 2007, 204:610-618.
57. Wojcik S., Nogalska A., Engel W.K., Askanas V. Myostatin and its precursor protein are increased in the skeletal muscle of patients with Type-II muscle fibre atrophy. Folia Morphol. (Warsz) 2008, 67:6-12.
58. Gonzalez-Cadavid N.F., Taylor W.E., Yarasheski K., Sinha-Hikim I., Ma K., Ezzat S., Shen R., Lalani R., Asa S., Mamita M., Nair G., Arver S., Bhasin S. Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:14938-14943.
59. Zhou X., Wang J.L., Lu J., Song Y., Kwak K.S., Jiao Q., Rosenfeld R., Chen Q., Boone T., Simonet W.S., Lacey D.L., Goldberg A.L., Han H.Q. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010, 142:531-543.
60. Lavenstein B., Engel W.K., Reddy N.B., Carroll S. Autoradiographic visualization of beta-adrenergic receptors in normal and denervated skeletal muscle. J. Histochem. Cytochem. 1979, 27:1308-1311.
61. Joassard O.R., Durieux A.C., Freyssenet D.G. beta2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders. Int. J. Biochem. Cell Biol. 2013, 45:2309-2321.
62. Tsuzuki K., Fukatsu R., Takamaru Y., Yoshida T., Hayashi Y., Yamaguchi H., Fujii N., Takahata N. Amyloid beta protein in rat soleus muscle in chloroquine-induced myopathy using end-specific antibodies for A beta 40 and A beta 42: immunohistochemical evidence for amyloid beta protein. Neurosci. Lett. 1995, 202:77-80.
63. Whitaker J.N., Engel W.K. Vascular deposits of immunoglobulin and complement in idiopathic inflammatory myopathy. N. Engl. J. Med. 1972, 286:333-338.
64. Whitaker J.N., Engel W.K. Mechanisms of muscle injury in idiopathic inflammatory myopathy. N. Engl. J. Med. 1973, 289:107-108.
65. Oldfors A., Moslemi A.R., Jonasson L., Ohlsson M., Kollberg G., Lindberg C. Mitochondrial abnormalities in inclusion-body myositis. Neurology 2006, 66:S49-S55.
66. Engel W.K. "Ragged-red fibers" in opthamoplegia syndromes and their differential diagnosis. Excerpta Med. Int. Congr. Ser. 1971, 237.
67. Di Mauro S., Schon E.A., Hirano M. Mitochondrial changes in aging wih particular reference to muscle, and possible clinical consequences. Muscle aging, inclusion-body myositis and myopathies 2011, Wiley. V. Askanas, W.K. Engel (Eds.).
68. Engel W.K., Eyerman E.J., Williams H.E. Late-onset type of skeletal muscle phosphorylase deficiency: a new familial variety of completely or partially affected subjects. N. Engl. J. Med. 1963, 268:135-137.
69. Askanas V., Engel W.K. Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol. 2008, 116:583-595.
70. Askanas V., Engel W.K., Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol. 2009, 19:493-506.
71. Askanas V., Engel W.K., Nogalska A. Pathogenesis, including role of cellular aging, abnormal accumulation of proteins that are also accumulated in brains of neurodegenerative disorders, and possible treatment avenues. Muscle aging, inclusion-body myositis and myopathies 2011, Wiley. V. Askanas, W.K. Engel (Eds.).
72. Nogalska A., D'Agostino C., Cacciottolo M., Engel W.K., Askanas V. Abnormalities of mitophagy in sporadic inclusion-body myositis (s-IBM) muscle fibers. Neurology 2014, 82:P3.288.
73. Engel W.K., Askanas V. Toxic role of long-chain fatty acids in muscle carnitine deficiency and other LCFA restriction associated with dramatic long-term improvemenet. Neurology 1986, 36:94.
74. Engel W.K., Askanas V. Toxicity of long-chain fattty acids in muscle carnitine deficiency and remarkable improvement being sustained 21years by strict dietary restriction of LCFAs. An endodissolution phenomenon?. Neurology 2003, 60:A465.
75. Prockop L.D., Engel W.K., Shug A.L. Nearly fatal muscle carnitine deficiency with full recovery after replacement therapy. Neurology 1983, 33:1629-1631.
76. Askanas V., Engel W.K., Kwan H.H., Reddy N.B., Husainy T., Carlo J., Siddique T., Schwartzman R.J., Hanna C.J. Autosomal dominant syndrome of lipid neuromyopathy with normal carnitine: successful treatment with long-chain fatty-acid-free diet. Neurology 1985, 35:66-72.
77. Argov Z., Nishino I., Nonaka I. Clinical and ethnic spectum, laboratory data and epidemiology of h-IBM due to GNE mutations. Muscle aging, inclusion-body myositis and myopathies 2011, Wiley. V. Askanas, W.K. Engel (Eds.).
78. Dec E., Rana P., Katheria V., Dec R., Khare M., Nalbandian A., Leu S.Y., Radom-Aizik S., Llewellyn K., BenMohamed L., Zaldivar F., Kimonis V. Cytokine profiling in patients with VCP-associated disease. Clin Transl Sci 2014, 7:29-32.
79. Griggs R.C., Engel W.K., Resnick J.S. Acetazolamide treatment of hypokalemic periodic paralysis. Prevention of attacks and improvement of persistent weakness. Ann. Intern. Med. 1970, 73:39-48.
80. Resnick J.S., Engel W.K., Griggs R.C., Stam A.C. Acetazolamide prophylaxis in hypokalemic periodic paralysis. N. Engl. J. Med. 1968, 278:582-586.
81. Dalakas M.C., Engel W.K. Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis. Muscle Nerve 1983, 6:182-186.
82. Engel W.K., Bishop D.W., Cunningham G.G. Tubular aggregates in type II muscle fibers: ultrastructural and histochemical correlation. J. Ultrastruct. Res. 1970, 31:507-525.
83. Lossos A., Teltsh O., Milman T., Meiner V., Rozen R., Leclerc D., Schwahn B.C., Karp N., Rosenblatt D.S., Watkins D., Shaag A., Korman S.H., Heyman S.N., Gal A., Newman J.P., Steiner-Birmanns B., Abramsky O., Kohn Y. Severe methylenetetrahydrofolate reductase deficiency: clinical clues to a potentially treatable cause of adult-onset hereditary spastic paraplegia. JAMA Nneurol. 2014, 71:901-904.
84. Engel W.K. Does a retrovirus cause amyotrophic lateral sclerosis?. Ann. Neurol. 1991, 30:431-433.
85. Engel W.K. RNA metabolism in relation to amyotrophic lateral sclerosis. Adv. Neurol. 1991, 56:125-153.
86. Engel W.K., Kurland L.T., Klatzo I. An inherited disease similar to amyotrophic lateral sclerosis with a pattern of posterior column involvement. An intermediate form?. Brain 1959, 82:203-220.
87. Engel W.K., Askanas V. Current research approaches to the amyotrophic lateral sclerosis syndrome. Part I: General hypotheses, uridine, liver, dyslymphocytic mechanisms, B12 plus folate, parathyroid. Myélopathies, neuropathies Et myopathies. Advances in neuromuscular diseases 1989, 57-76. Expansion Scientifique Francaise, Paris. G. Serratrice (Ed.).
88. Engel W.K., Askanas V., Alvarez R.B., Sarkozi E. Oxidative stress demonstrated histologically in ALS astrocytes, harmonizing with the hypothesis that malfunction of astrocytes may underlie sporadic ALS. Neurology 1998, 50:430.
89. Engel W.K. In ALS, viral-dysmetabolic mechanism acting via neuronal-nurturing cells (NNCs) could portend replacement therapy and should be sought by multi-tissue screening for rev-transcriptase (RT) viral tracks. Neuromuscul. Disord. 2008, 74:A465.
90. Engel W.K., Patterson J.M., Tauzin M.R., Kern W.H. Liver-biopsy abnormalities in amyotropic lateral sclerosis. Ann. Neurol. 1988, 24:163.
91. Engel W.K. Q-Fever IgM-Positivity in 3/5 sALS patients: any pathogenic significance regarding the XYZ Hypothesis. Ann. Neurol. 2012, 72(16):S68.
92. Engel W.K. Duschenne muscular dystrophy: a histologically based ischemia hypothesis and comparison with experimental ischemia myopathy. The Striated Muscle 1973, vol. 12:453-472. Wiliams & Wilkins Co, Baltimore.
93. Engel W.K. Integrative histochemical approach to the defect of Duschenne muscular dystrophy. Pathogenesis of the human muscular dystrophies 1977, 277-309. American Elsevier Publishing Co, New York. L.P. Rowland (Ed.).
94. Mendell J.R., Engel W.K., Derrer E.C. Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science 1971, 172:1143-1145.
95. Mendell J.R., Engel W.K., Derrer E.C. Increased plasma enzyme concentrations in rats with functional ischaemia of muscle provide a possible model of Duchenne muscular dystrophy. Nature 1972, 239:522-524.
96. Nelson M.D., Rader F., Tang X., Tavyev J., Nelson S.F., Miceli M.C., Elashoff R.M., Sweeney H.L., Victor R.G. PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. Neurology 2014, 82:2085-2091.
97. Engel W.K., Trotter J.L. Plasma-cell dyscrasic amyloid neuropathy: a parasparafucile phenomenon?. Peroneal atrophies and related disorders 1979, 339-347. Masson Publishing Co, New York. G. Serratice, H. Roux (Eds.).
98. Engel W.K. Intravenous immunoglobulin (IVIG) - an aften overlooked treatment- produces rapid, remarkable, sustained benefit in "Diabetic Neuropathy Complex", suggesting a dysimmune mechanism. Ann. Neurol. 1997, 42:414.
99. Engel W.K. Intravenous immunoglobulin G is remarkably beneficial in chronic immune dysschwannian/dysneuronal polyneuropathy, diabetes-2 neuropathy, and potentially in severe acute respiratory syndrome. Acta Myol. 2003, 22:97-103.
100. Engel W.K. Longer-term (>3months), IVIG treatment to optimize clinical benefit and cellular protection usually requires an individualized adjustable schedule- not fixed regimentation. Neuromuscul. Disord. 2006, 16:703-704.
101. Mahajan S., Engel W.K., Askanas V., Luthra I., Gupta V. Adult onset rod myopathy syndrome: sustained benefit from IVIG and rituximab. Ann. Neurol. 2011, 70:s39.
102. Ceribelli M., Kelly P.N., Shaffer A.L., Wright G.W., Xiao W., Yang Y., Mathews Griner L.A., Guha R., Shinn P., Keller J.M., Liu D., Patel P.R., Ferrer M., Joshi S., Nerle S., Sandy P., Normant E., Thomas C.J., Staudt L.M. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:11365-11370.
103. Smith D.D., Goldstein L., Cheng M., James D.F., Kunkel L.A., Fardis M., Hamdy A., Izumi R., Buggy J.J., Clow F. Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib. Ann. Hematol. 2014, 10.1007/s00277-014-2187-9.
104. Dalakas M.C., Engel W.K. Polyneuropathy with monoclonal gammopathy: studies of 11 patients. Ann. Neurol. 1981, 10:45-52.
105. Dalakas M.C., Engel W.K. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann. Neurol. 1981, 9:134-145. (Suppl.).
106. Engel W.K., Mahajan S., Askanas V. Aging of the human neuromuscular system: patients vignettes. Muscle aging, inclusion-body myositis and myopathies 2011, Wiley-Blackwell. V. Askanas, W.K. Engel (Eds.).
107. Engel W.K. "Pseudo-lupus", benign neutropenia, and other probable non-worrisome blood-component chantges due to IVIG treatment. Neuromuscul. Disord. 2006, 16:647-648.
108. Engel W.K. In Type-2 Diabetes (D2), diabetic neuropathy and diabeto-2-genetic (D2-Gen) neuropathy are often dysimmune and respond to intravenous IGG (IVIG) treatment. Neuroscience 2001, A27.
109. Engel W.K., Spath The use of intravenous immunoglobulins in neurology. Intravenous immunoglobulins in the third millinnium 2004, 377-382. The Parthenon Publishing Group. M.C. Dalakas (Ed.).
110. Thomas P.K., Eliasson S.G. Diabetic neuropathy. Peripheral Neuropathy 1975, vol. 2:956-981. W.B. Saunders Company, Philadelphia.
111. Bishoff A. Die Diabetische Neuropahtie 1963, Gustav Thieme Verlag, Stuttgart.
112. Engel W.K., Prentice A.F. Some polyneuropathies (PNs) in insulin-requiring adult-onset diabetes (IRAOD) an benefit remarkably from anti-dysiimune treatments. Neurology 1993, 43:255-256.
113. Callaghan B.C., Cheng H.T., Stables C.L., Smith A.L., Feldman E.L. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012, 11:521-534.
114. Engel W.K., McFarlin D.E. Muscle lesions in myasthenia gravis. Discussion. Ann. N. Y. Acad. Sci. 1966, 135:68-78.
115. Ringel S.P., Bender A.N., Engel W.K. Extrajunctional acetylcholine receptors. Alterations in human and experimental neuromuscular diseases. Arch. Neurol. 1976, 33:751-758.
116. Bender A.N., Ringel S.P., Engel W.K., Vogel Z., Daniels M.P. Immunoperoxidase localization of alpha bungarotoxin: a new approach to myasthenia gravis. Ann. N. Y. Acad. Sci. 1976, 274:20-30.
117. Engel W.K., Trotter J.L., McFarlin D.E. Thymic epithelial cell contains acetylocholine receptor. Lancet 1977, 1:1310-1311.
118. Engel W.K., Warmolts J.R. Myasthenia gravis: a new hypothesis of the pathogenesis and a new form of treatment. Ann. N. Y. Acad. Sci. 1971, 183:72-87.
119. Warmolts J.R., Engel W.K. Benefit from alternate-day prednisone in myasthenia gravis. N. Engl. J. Med. 1972, 286:17-20.
120. Warmolts J.R., Engel W.K., Whitaker J.N. Alternate-dy prednisone in a patient with myasthenia gravis. Lancet 1970, 2:1198-1199.
121. Dalakas M., Engel W.K. Total body irradiation in the treatment od intractable polymyosistis and dermatomyositis. Polymyosistis 1988, 281-292. Butterworths, Boston. M. Dalakas (Ed.).
122. Engel W.K., Lichter A.S., Galdi A.P. Polymyositis: remarkable response to total body irradiation. Lancet 1981, 1:658.
123. Engel W.K., Lichter A.S., Siddique T. Remarkable improvement sustained 1-2 years following total body irradiation treatment of otherwise intractable adult polymyositis/dermatomyositis. Neurology 1982, 32:120.
124. Engel W.K. Fever-responsive dysschwannian neuropathy (FRDN): Interferon-alpha 2a (Interferon α- 2a (Iα)treatment has produced remarkable recovery from total quadriplegia, the benefit now persisting 4years beyond the 14years of therapy. Neuromuscul. Disord. 2007, 17:885.
125. Engel W.K., Adornato B. Fever-responsive neuropathy (FRN) benefited by long-term interferon alpha-2A (Iα) treatment. Can. J. Neurol. Sci. 1993, 4:S44.
126. Engel W.K., Askanas V. Letter: Overlooked avian oncornavirus in cultured muscle-functionally significant?. Science 1976, 192:1252-1253.
127. Shy G.M., Engel W.K., Somers J.E., Wanko T. Nemaline myopathy. A new congenital myopathy. Brain 1963, 86:793-810.
128. Engel W.K., Wanko T., Fenichel G.M. Nemaline myopathy; a second case. Arch. Neurol. 1964, 11:22-39.
129. Gupta V.A., Ravenscroft G., Shaheen R., Todd E.J., Swanson L.C., Shiina M., Ogata K., Hsu C., Clarke N.F., Darras B.T., Farrar M.A., Hashem A., Manton N.D., Muntoni F., North K.N., Sandaradura S.A., Nishino I., Hayashi Y.K., Sewry C.A., Thompson E.M., Yau K.S., Brownstein C.A., Yu T.W., Allcock R.J., Davis M.R., Wallgren-Pettersson C., Matsumoto N., Alkuraya F.S., Laing N.G., Beggs A.H. Identification of KLHL41 mutations implicates BTB-kelch-mediated ubiquitination as an alternate pathway to myofibrillar disruption in nemaline myopathy. Am. J. Hum. Genet. 2013, 93:1108-1117.
130. Ravenscroft G., Miyatake S., Lehtokari V.L., Todd E.J., Vornanen P., Yau K.S., Hayashi Y.K., Miyake N., Tsurusaki Y., Doi H., Saitsu H., Osaka H., Yamashita S., Ohya T., Sakamoto Y., Koshimizu E., Imamura S., Yamashita M., Ogata K., Shiina M., Bryson-Richardson R.J., Vaz R., Ceyhan O., Brownstein C.A., Swanson L.C., Monnot S., Romero N.B., Amthor H., Kresoje N., Sivadorai P., Kiraly-Borri C., Haliloglu G., Talim B., Orhan D., Kale G., Charles A.K., Fabian V.A., Davis M.R., Lammens M., Sewry C.A., Manzur A., Muntoni F., Clarke N.F., North K.N., Bertini E., Nevo Y., Willichowski E., Silberg I.E., Topaloglu H., Beggs A.H., Allcock R.J., Nishino I., Wallgren-Pettersson C., Matsumoto N., Laing N.G. Mutations in KLHL40 are a frequent cause of severe autosomal-recessive nemaline myopathy. Am. J. Hum. Genet. 2013, 93:6-18.
131. Laing N.G. Nemaline myopathy and related diseases: genetics, diagnosis and theraphy. J. Neuromuscul. Dis. 2014, 1:S38-S39.
132. Mahajan S., Engel W.K. Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010, 75:1397-1398.
133. Engel W.K., Misra A.K., Alexander S.J. Syndrome of continuous motor unit activity responsible to immunosupression suggest dysimmune pathogenesis. Neurology 1990, 40:118.
134. Engel W.K., Hanna C.J., Misra A.K. HTLV-I-associated myelopathy. N. Engl. J. Med. 1990, 323:552.